SVRA — Savara Inc. stock price, charts and financials

QT64Savara Inc.

Savara Inc. (NASDAQ: SVRA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
5.37
-0.05-0.92%
OverviewShort InterestFilings
SVRAQT64Savara Inc.·NASDAQ
5.37-0.92%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
RAPP-3.58%$40.45GHRS-1.60%$28.26AGIO-1.61%$33.07ZBIO-1.47%$31.50ADMA+1.79%$9.11VCEL-0.03%$40.02RXRX+8.19%$3.83KOD-0.43%$32.71
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand204.93MPerf Week1.32%
Market Cap1.10BForward P/E-EPS next Y-0.36Insider Trans-0.15%Shs Float106.86MPerf Month-3.76%
Enterprise Value957.46MPEG-EPS next Q-0.16Inst Own-Short Float38.77%Perf Quarter-2.36%
Income-119.00MP/S0.00EPS this Y-Inst Trans-Short Ratio22.92Perf Half Y4.07%
Sales0.00P/B7.64EPS next Y61.86%ROA-72.50%Short Interest41.43MPerf YTD-10.95%
Book/sh0.70P/C6.36EPS next 5Y-ROE-90.28%52W High7.01 -23.40%Perf Year49.17%
Cash/sh0.84P/FCF-EPS past 3/5Y-ROIC-82.30%52W Low3.34 60.78%Perf 3Y46.32%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility3.64% 3.67%Perf 5Y270.34%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-20.83%Oper. Margin0.00%ATR (14)0.22Perf 10Y-
Dividend Ex-Date-Quick Ratio10.13Sales Y/Y TTM-Profit Margin0.00%RSI (14)48.41Recom2.18
Dividend Gr. 3/5Y-Current Ratio10.13EPS Q/Q-14.29%SMA20-0.68%Beta0.18Target Price9.50
Payout0.00%Debt/Eq0.15Sales Q/Q-SMA50-2.38%Rel Volume1.28Prev Close5.42
Employees70LT Debt/Eq0.15EarningsNov 11SMA200-3.99%Avg Volume1.70MPrice5.37
IPO DateApr 28, 2017Option/ShortYes / YesEPS/Sales Surpr.-13.27% -Net Debt/EBITDA0.08Volume2,181,879Change-0.92%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-16-26ReiteratedWilliam Blair$10
Dec-23-25ReiteratedOppenheimerOutperform$11 → $10
Dec-23-25ReiteratedUBS$10
Oct-23-25ReiteratedJMP SecuritiesMarket Outperform$9.00 → $11
Sep-09-25ReiteratedGuggenheimBuy$10 → $11
Aug-15-25UpgradeHC Wainwright & Co.Neutral → Buy$10 → $5.00
May-29-25DowngradeHC Wainwright & Co.Buy → Neutral
Nov-13-24DowngradeEvercore ISI GroupOutperform → In Line
Aug-13-24ReiteratedJMP SecuritiesMarket Outperform$10 → $9.00
Jun-27-24ReiteratedJMP SecuritiesMarket Outperform$10
Latest News· Times ET
Aug-31-26
Aug-31-2612:21AM
BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRAdefenseworld.net
Aug-26-26
Aug-26-2611:35PM
Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRAdefenseworld.net
Aug-25-26
Aug-25-2612:19AM
Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRAdefenseworld.net
Aug-24-26
Aug-24-2612:08PM
Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS CongressBenzinga
12:05PM
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026businesswire.com
Aug-20-26
Aug-20-2612:05PM
Savara Announces New Employment Inducement Grantbusinesswire.com
Aug-18-26
Aug-18-2605:00PM
Top movers in Tuesday's after hours sessionChartMill
Aug-11-26
Aug-11-2601:01PM
Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041Benzinga
12:05PM
Savara Reports Second Quarter 2026 Financial Results and Provides Business Updatebusinesswire.com
Aug-05-26
Aug-05-2602:25AM
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bumpseekingalpha.com
Jul-30-26
Jul-30-2604:05AM
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041businesswire.com
Jul-22-26
Jul-22-2606:26AM
Here's Why You Should Add Savara Stock to Your Portfolio Nowzacks.com
Jun-27-26
Jun-27-2607:14AM
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timelinefool.com
Company

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000——————
Cost of Goods Sold Incl. D&A07844——————
Gross Profit0-78-44——————
Selling, General and Administrative Excl. Other422516——————
Research and Development817844——————
Other Operating Expense0-78-44——————
Operating Income-124-103-60——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)575——————
Net Income Before Taxes-119-96-55——————
Income Taxes
000——————
Consolidated Net Income-119-96-55——————
Net Income From Continuing Operations-119-96-55——————
Net Income-119-96-55——————
EPS (Recurring)-0.53-0.48-0.33——————
EPS (Basic, Before Extraordinaries)-0.53-0.48-0.33——————
EPS (Diluted)-0.53-0.48-0.33——————
EBITDA-119-102-59——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding222198165——————
Market Capitalization1,339608776——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$7.64$6.12$4.60$3.08$1.56● Close Price0.00M0.56M1.12M1.68M2.24MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Lowrance David LChief Financial OfficerJun 22 '26Option Exercise1.76580,1871,021,117983,947Jun 22
Lowrance David LChief Financial OfficerJun 22 '26Sale5.68394,5282,241,432536,032Jun 22
Lowrance David LChief Financial OfficerMar 18 '26Option Exercise1.60366,747588,456552,550Mar 20
McCracken Joseph SDirectorFeb 16 '26Option Exercise1.761,8073,180302,644Feb 17
RAMSAY DAVID ADirectorDec 19 '25Sale6.0620,000121,2202,533,642Dec 19
Elam Nevan CDirectorDec 02 '25Option Exercise1.465,8608,55668,360Dec 04
Hawkins Richard JDirectorNov 14 '25Option Exercise1.465,8608,556121,326Nov 17
Hawkins Richard JDirectorJun 20 '25Buy2.0448,22598,572115,466Jun 23
McCracken Joseph SDirectorMay 29 '25Buy2.0810,00020,825260,837Jun 02
RAMSAY DAVID ADirectorMar 31 '25Buy2.77150,000416,2502,513,642Apr 01
Pauls MatthewCHIEF EXECUTIVE OFFICERDec 16 '24Sale3.3154,702180,8281,536,379Dec 16
Lowrance David LChief Financial OfficerDec 16 '24Sale3.3325,00083,278381,005Dec 16
Hawkins Richard JDirectorDec 16 '24Sale3.328,00026,56967,241Dec 16
McCracken Joseph SDirectorNov 19 '24Buy2.9520,00059,072210,837Nov 20
RAMSAY DAVID ADirectorNov 18 '24Buy2.88100,000287,6002,323,642Nov 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.